ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
September 11, 2024 12:07 ET
|
Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
September 09, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) --...
ORYZON to Provide Corporate Progress Updates at Several Events in September
August 29, 2024 08:14 ET
|
Oryzon Genomics, S.A.
German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE...
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
July 31, 2024 08:32 ET
|
Oryzon Genomics, S.A.
Company granted an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial with vafidemstat in Borderline Personality Disorder (BPD)Final data from PORTICO, global...
Oryzon to Attend the 36th Annual Cowen Health Care Conference
February 23, 2016 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum
February 16, 2016 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics to Present at the 18th Annual BIO CEO & Investor Conference 2016
February 02, 2016 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
February 01, 2016 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon Genomics to Present at the Epigenetics in Drug Discovery Workshop
January 26, 2016 16:30 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
January 05, 2016 08:00 ET
|
Oryzon
BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...